Abstract
This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)–pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin’s lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Indeed, a lower incidence of chronic GVHD was observed in the BV group, with a 43% cumulative incidence at 3 years versus 47% in the no BV group, although this was not statistically significant. Despite the low incidence of chronic GVHD, survival was not worse in the BV-treated group: 3-year progression-free survival (PFS) was 53%, 3-year overall survival (OS) was 62%, 3-year non-relapse mortality (NRM) was 24%. In the no BV group, the 3-year PFS was 33%, 3-year OS was 44%, and 3-year NRM was 14%. In chemorefractory patients at the time of transplant, we found a statistically significant difference in PFS between the BV and no BV groups (51% vs. 10%, p = 0.013).
| Original language | English |
|---|---|
| Journal | Annals of Hematology |
| DOIs | |
| Publication status | Published - Jan 1 2019 |
Fingerprint
Keywords
- Allogeneic stem cell transplant
- Brentuximab vedotin
- Hodgkin lymphoma
ASJC Scopus subject areas
- Hematology
Cite this
Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients. / Gaudio, Francesco; Mazza, Patrizio; Mele, Anna; Palazzo, Giulia; Carella, Angelo Michele; Delia, Mario; Pisapia, Giovanni; Pastore, Domenico; Cascavilla, Nicola; Pavone, Vincenzo; Specchia, Giorgina.
In: Annals of Hematology, 01.01.2019.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin’s lymphoma patients
AU - Gaudio, Francesco
AU - Mazza, Patrizio
AU - Mele, Anna
AU - Palazzo, Giulia
AU - Carella, Angelo Michele
AU - Delia, Mario
AU - Pisapia, Giovanni
AU - Pastore, Domenico
AU - Cascavilla, Nicola
AU - Pavone, Vincenzo
AU - Specchia, Giorgina
PY - 2019/1/1
Y1 - 2019/1/1
N2 - This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)–pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin’s lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Indeed, a lower incidence of chronic GVHD was observed in the BV group, with a 43% cumulative incidence at 3 years versus 47% in the no BV group, although this was not statistically significant. Despite the low incidence of chronic GVHD, survival was not worse in the BV-treated group: 3-year progression-free survival (PFS) was 53%, 3-year overall survival (OS) was 62%, 3-year non-relapse mortality (NRM) was 24%. In the no BV group, the 3-year PFS was 33%, 3-year OS was 44%, and 3-year NRM was 14%. In chemorefractory patients at the time of transplant, we found a statistically significant difference in PFS between the BV and no BV groups (51% vs. 10%, p = 0.013).
AB - This study reports a retrospective multicenter experience by the Rete Ematologica Pugliese (REP) over the past 16 years, aiming to compare the patients characteristics and outcomes of 21 brentuximab vedotin (BV)–pre-treated patients to 51 patients who received reduced-intensity conditioning (RIC) allogeneic stem cell transplantation (SCT) without prior BV. In total, 72 patients with classical Hodgkin’s lymphomas who received allogeneic SCT were retrospectively studied. Prior use of BV had no effect on either engraftment or the incidence and severity of acute graft versus host disease (GVHD). Indeed, a lower incidence of chronic GVHD was observed in the BV group, with a 43% cumulative incidence at 3 years versus 47% in the no BV group, although this was not statistically significant. Despite the low incidence of chronic GVHD, survival was not worse in the BV-treated group: 3-year progression-free survival (PFS) was 53%, 3-year overall survival (OS) was 62%, 3-year non-relapse mortality (NRM) was 24%. In the no BV group, the 3-year PFS was 33%, 3-year OS was 44%, and 3-year NRM was 14%. In chemorefractory patients at the time of transplant, we found a statistically significant difference in PFS between the BV and no BV groups (51% vs. 10%, p = 0.013).
KW - Allogeneic stem cell transplant
KW - Brentuximab vedotin
KW - Hodgkin lymphoma
UR - http://www.scopus.com/inward/record.url?scp=85062903858&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062903858&partnerID=8YFLogxK
U2 - 10.1007/s00277-019-03662-6
DO - 10.1007/s00277-019-03662-6
M3 - Article
C2 - 30868307
AN - SCOPUS:85062903858
JO - Annals of Hematology
JF - Annals of Hematology
SN - 0939-5555
ER -